| 1. |
- Chrcanovic, Bruno Ramos, DDS, MSc, PhD, et al.
(författare)
-
Comparison of survival outcomes between ameloblastic carcinoma and metastasizing ameloblastoma : a systematic review
- 2022
-
Ingår i: Journal of Oral Pathology & Medicine. - : John Wiley & Sons. - 0904-2512 .- 1600-0714. ; 51:7, s. 603-610
-
Tidskriftsartikel (refereegranskat)abstract
- PURPOSE: To investigate and compare the demographic data, occurrence of recurrence and metastasis, and survival prognosis between ameloblastic carcinoma and metastasizing ameloblastoma, based on appropriate and currently accepted eligible diagnostic criteria, in a systematic review of the literature.METHODS: An electronic search was undertaken, last updated in December 2021. Eligibility criteria included publications having enough clinicopathological information to confirm the diagnosis of these tumors.RESULTS: Seventy-seven publications reporting 85 ameloblastic carcinomas and 43 metastasizing ameloblastomas were included. Both tumors were more frequent in mandible and showed different clinical profiles regarding patients' sex and age. There was no difference in the estimated cumulative survival between patients diagnosed with these tumors. Metastases mainly affected the lungs, followed by cervical lymph nodes. The mean time between the first metastasis and the last follow-up was higher for metastasizing ameloblastoma (p=0.021). Additionally, metastasizing ameloblastoma patients remained alive longer than ameloblastic carcinoma patients after the first metastasis diagnosis (p=0.041). Considering only the cases that metastasized, a higher ratio of ameloblastic carcinoma patients died in comparison to metastasizing ameloblastoma patients (p=0.003). The occurrence of recurrence was associated with a conservative primary treatment with both ameloblastic carcinoma (p<0.001) and metastasizing ameloblastoma tumors (p=0.017). Multiple recurrent events were associated with conservative primary therapies with metastasizing ameloblastoma (p<0.001) but not with ameloblastic carcinoma (p=0.121).CONCLUSIONS: In addition to some demographic differences, ameloblastic carcinomas that metastasize present a worse prognosis than metastasizing ameloblastoma. As conservative procedures are associated with multiple recurrent events, this treatment modality should be avoided for both tumors. This article is protected by copyright. All rights reserved.
|
|
| 2. |
- Chrcanovic, Bruno Ramos, DDS, MSc, PhD, et al.
(författare)
-
Pyodermatitis-pyostomatitis vegetans : a case report and systematic review focusing on oral involvement
- 2024
-
Ingår i: Oral and Maxillofacial Surgery. - : Springer Berlin/Heidelberg. - 1865-1550 .- 1865-1569.
-
Tidskriftsartikel (refereegranskat)abstract
- BackgroundPyodermatitis-pyostomatitis vegetans (PPV) is a rare mucocutaneous disease characterized by multiple pustules and it is considered a marker for inflammatory bowel disease (IBD). The oral manifestations of this condition are referred to as pyostomatitis vegetans (PSV).PurposeTo investigate which features could help in establishing the diagnosis of PSV, with or without cutaneous lesions, based on information retrieved from all cases of PSV described in the literature. A case of PV from the authors was also included in the analysis.MethodsAn electronic search was undertaken, last updated in August 2022. Inclusion criteria included publications reporting cases of PSV, with the diagnosis confirmed by the pathological examination of oral or skin lesions, and presence of IBD.Results/ConclusionsSixty-two publications with 77 cases of PSV and an associated IBD were included. Features that are helpful in establishing the diagnosis of PSV are snail track appearance of oral lesions, an associated IBD (which is not always symptomatic), evidence of intraepithelial clefting on microscopic examination of oral lesions, and peripheral blood eosinophilia. A gold standard for the management of PSV does not exist and high-level evidence is limited. There is no established therapeutic protocol for PSV and management primarily consists of topical and/or systemic corticosteroids, antirheumatic drugs (sulfasalazine, mesalazine), monoclonal antibody (infliximab, adalimumab) immunosuppressives (azathioprine, methotrexate), antibiotics (dapsone), or a combination of these. The risk of recurrence of oral lesions is considerable when the medication dose is decreased or fully interrupted.
|
|
